Literature DB >> 22640713

Cervical cancer.

Jayanthi S Lea1, Ken Y Lin.   

Abstract

Squamous cell cervical cancer incidence and mortality have been reduced dramatically as a result of successful screening in many countries. The incidence of cervical adenocarcinoma continues to increase. There has been concentrated effort toward improving early detection and screening by utilizing molecular biomarker assays. The FIGO staging system for cervical cancer was revised in 2009. Fertility preservation can be offered to patients with early-stage cervical cancer through radical trachelectomy, although radical hysterectomy remains the surgical standard of care. Concurrent chemotherapy with radiation has been shown to have a survival advantage in patients with advanced-stage disease. Improvements in radiation techniques and molecular targeted therapy are the current research venues in cervical cancer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22640713     DOI: 10.1016/j.ogc.2012.02.008

Source DB:  PubMed          Journal:  Obstet Gynecol Clin North Am        ISSN: 0889-8545            Impact factor:   2.844


  19 in total

Review 1.  Primary malignant melanomas of the female lower genital tract: clinicopathological characteristics and management.

Authors:  Dongying Wang; Tianmin Xu; He Zhu; Junxue Dong; Li Fu
Journal:  Am J Cancer Res       Date:  2020-12-01       Impact factor: 6.166

2.  Morusin inhibits human cervical cancer stem cell growth and migration through attenuation of NF-κB activity and apoptosis induction.

Authors:  Li Wang; Huijie Guo; Liuqi Yang; Lihua Dong; Caiyu Lin; Jie Zhang; Ping Lin; Xiujie Wang
Journal:  Mol Cell Biochem       Date:  2013-03-31       Impact factor: 3.396

3.  Forkhead box protein O1 (FOXO1) and paired box gene 3 (PAX3) overexpression is associated with poor prognosis in patients with cervical cancer.

Authors:  Doo Byung Chay; Gwan Hee Han; Sanghee Nam; Hanbyoul Cho; Joon-Yong Chung; Stephen M Hewitt
Journal:  Int J Clin Oncol       Date:  2019-07-13       Impact factor: 3.402

4.  Analysis of radiotherapy-induced alteration of CD8+ T cells and PD-L1 expression in patients with uterine cervical squamous cell carcinoma.

Authors:  Yasumasa Mori; Hiro Sato; Takuya Kumazawa; Tiara Bunga Mayang Permata; Yuya Yoshimoto; Kazutoshi Murata; Shin-Ei Noda; Takuya Kaminuma; Ken Ando; Takahiro Oike; Noriyuki Okonogi; Kohei Okada; Sangeeta Kakoti; Keiji Suzuki; Hayato Ikota; Hideaki Yokoo; Takashi Nakano; Tatsuya Ohno; Atsushi Shibata
Journal:  Oncol Lett       Date:  2021-04-06       Impact factor: 2.967

Review 5.  Novel Insight of CircRNAs in Cervical Cancer: Potential Biomarkers and Therapeutic Target.

Authors:  Maomao Wu; Yanxun Han; Xiangfei Gong; Ke Wan; Yuchen Liu; Yi Zhou; Lizhi Zhang; Guozheng Tang; Hui Fang; Bangjie Chen; Fan Yang; Qing Zhao; Genbao Wang; Chenghao Zhanghuang; Yunling Zhang
Journal:  Front Med (Lausanne)       Date:  2022-06-23

6.  Incidence and mortality of cervical cancer in China, 2013.

Authors:  Bingbing Song; Chao Ding; Wangyang Chen; Huixin Sun; Maoxiang Zhang; Wanqing Chen
Journal:  Chin J Cancer Res       Date:  2017-12       Impact factor: 5.087

7.  Enrichment and characterization of cancer stem‑like cells from a cervical cancer cell line.

Authors:  Li Wang; Huijie Guo; Caiyu Lin; Liuqi Yang; Xiujie Wang
Journal:  Mol Med Rep       Date:  2014-03-20       Impact factor: 2.952

8.  Awareness of cervical cancer risk factors and symptoms: cross-sectional community survey in post-conflict northern Uganda.

Authors:  Amos D Mwaka; Christopher G Orach; Edward M Were; Georgios Lyratzopoulos; Henry Wabinga; Martin Roland
Journal:  Health Expect       Date:  2015-07-23       Impact factor: 3.377

9.  Increased CCL19 expression is associated with progression in cervical cancer.

Authors:  Xiaoshu Zhang; Yue Wang; Yanning Cao; Xueshan Zhang; Haiya Zhao
Journal:  Oncotarget       Date:  2017-05-18

10.  Over-Expressed miR-224 Promotes the Progression of Cervical Cancer via Targeting RASSF8.

Authors:  YongJie Huang; Yang Li; Fen F Wang; WeiGuo Lv; Xing Xie; Xiaodong Cheng
Journal:  PLoS One       Date:  2016-09-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.